Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Capital Expenditures (2022 - 2026)

Zentalis Pharmaceuticals has reported Capital Expenditures over the past 4 years, most recently at $34000.0 for Q1 2026.

  • For Q1 2026, Capital Expenditures changed N/A year-over-year to $34000.0; the TTM value through Mar 2026 reached $34000.0, down 81.22%, while the annual FY2024 figure was $221000.0, 62.09% down from the prior year.
  • Capital Expenditures for Q1 2026 was $34000.0 at Zentalis Pharmaceuticals, down from $181000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $2.3 million in Q3 2022 and troughed at -$135000.0 in Q2 2022.
  • A 4-year average of $338600.0 and a median of $166500.0 in 2022 define the central range for Capital Expenditures.
  • On a YoY basis, Capital Expenditures climbed as much as 336.3% in 2023 and fell as far as 96.04% in 2023.
  • Year by year, Capital Expenditures stood at $160000.0 in 2022, then increased by 8.12% to $173000.0 in 2023, then increased by 4.62% to $181000.0 in 2024, then tumbled by 81.22% to $34000.0 in 2026.
  • Business Quant data shows Capital Expenditures for ZNTL at $34000.0 in Q1 2026, $181000.0 in Q2 2024, and $40000.0 in Q1 2024.